Skip to main content Skip to search Skip to main navigation

MDCG: Guidance on custom-made medical devices according to MDR

The Medical Device Coordination Group (MDCG) published an eight-page Q&A document titled Questions and Answers on Custom-Made Devices & considerations on Adaptable medical devices and Patient-matched medical devices (MDCG 2021-3) on 15 March 2021.

Ten pairs of questions and answers clarify how to deal with custom-made medical devices with regard to the new Medical Device Regulation (EU) 2017/745 (MDR).  

How are custom-made devices (CMDs) defined under the MDR?

  • They are specifically manufactured as prescribed by an authorized person under national law and based on their qualification.  
  • They have specific design characteristics provided by the responsible authorized person.  
  • They are intended for the exclusive use by a particular person to meet their individual conditions and needs.

Dental crowns, hand prostheses or orthoses are mentioned as examples.  

The Q&A clarifies the extent to which differences exist between custom-made, mass-produced and, for example, 3D-printed medical devices according to the new MDR. For example, manufacturers of "intermediates," which in turn are used to make or are combined with custom-made medical devices, must comply with MDR requirements.   

The MDCG is composed of representatives from all European member states, as well as a representative of the European Commission, who serves as chair. Thus, the Q&A is not a European Commission document and as such is not legally binding.


Source:

MDCG: Questions and Answers on Custom-Made Devices & considerations on Adaptable medical devices and Patient-matched medical devices

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ANVISA: Expands Recognition of Foreign GMP Authorities

ANVISA: Expands Recognition of Foreign GMP Authorities

Brazilian health authority ANVISA has updated the requirements for the recognition of Equivalent Foreign Regulatory Authorities (AREE) and the administrative procedures for Good Manufacturing Practice (GMP) certification (CBPF) through Normative Instruction IN 451/2026. The aim is to streamline and accelerate regulatory processes.
Read more
EDQM: Guidance on Reporting on Disappearances of Medicinal Products

EDQM: Guidance on Reporting on Disappearances of Medicinal Products

The EDQM has published guidance supporting the implementation of Recommendation CM/Rec(2024)3 on reporting medicinal products that disappear from the legal supply chain due to theft, loss or diversion. The initiative follows a European survey that identified shortcomings in reporting and co-ordination of such incidents.

Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
Previous
Next